Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Employees - 35,
CEO - Dr. Thomas J. Schuetz M.D., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 219.87M
Altman ZScore(max is 10): 8.72, Piotroski Score(max is 10): 4, Working Capital: $136707000, Total Assets: $149151000, Retained Earnings: $-349652000, EBIT: -55447000, Total Liabilities: $10753000, Revenue: $3694000
AryaFin Target Price - $0.17 - Current Price $1.59 - Analyst Target Price $13.10
| Ticker | CMPX |
| Index | RUT |
| Curent Price | 1.59 |
| Change | 1.27% |
| Market Cap | 219.87M |
| Average Volume | 2.07M |
| Income | -49.37M |
| Sales | 0.85M |
| Book Value/Share | 0.91 |
| Cash/Share | 0.92 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 35 |
| Moving Avg 20days | -23.61% |
| Moving Avg 50days | -41.03% |
| Moving Avg 200days | -12.22% |
| Shares Outstanding | 137.82M |
| Earnings Date | Feb 27 BMO |
| Inst. Ownership | 38.86% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 258.67 |
| Price/Book | 1.75 |
| Price/Cash | 1.74 |
| Price/FCF | - |
| Quick Ratio | 14.96 |
| Current Ratio | 14.96 |
| Debt/Equity | 0.05 |
| Return on Assets | -33.22% |
| Return on Equity | -36.07% |
| Return on Investment | -37.54% |
| Gross Margin | -106.24% |
| Ops Margin | -6661.53% |
| Profit Margin | -5808.59% |
| RSI | 33.84 |
| BETA(β) | 1.24 |
| From 52week Low | 107.84% |
| From 52week High | -61.03% |
| EPS | -0.36 |
| EPS next Year | -0.55 |
| EPS next Qtr | -0.11 |
| EPS this Year | -33.06% |
| EPS next 5 Year | 16.59% |
| EPS past 5 Year | -104.70% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -7.45% |
| Sales Y/Y | - |
| EPS Q/Q | -3.71% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -12.13% |
| ATR(14) | 0.27 |
| Perf Week | -29.02% |
| Perf Month | -32.91% |
| Perf Quarter | 0.63% |
| Perf Year | -6.47% |
| Perf YTD | 9.66% |
| Target Price | 13.10 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer